Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody.

[1]  M. Flowers,et al.  Chronic graft-versus-host disease. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  R. Looney.  Treating human autoimmune disease by depleting B cells , 2002, Annals of the rheumatic diseases.

[3]  M. Leandro,et al.  Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion , 2002, Annals of the rheumatic diseases.

[4]  G. Remuzzi,et al.  Rituximab for idiopathic membranous nephropathy , 2002, The Lancet.

[5]  J. Kurtzberg,et al.  Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease , 2002, Bone Marrow Transplantation.

[6]  H. Deeg,et al.  Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. , 2002, Blood.

[7]  J. Pober,et al.  Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease , 2002, The Lancet.

[8]  S. Amadori,et al.  Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. , 2002, Blood.

[9]  M. Luppi,et al.  Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment. , 2002, Blood.

[10]  W. May,et al.  Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation , 2002, Bone Marrow Transplantation.

[11]  M. Hogan,et al.  Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. , 2001, Arthritis and rheumatism.

[12]  D. Blaise,et al.  Enhanced activation of B cells in a granulocyte colony‐stimulating factor‐mobilized peripheral blood stem cell graft , 2001, British journal of haematology.

[13]  P. Lipsky.  Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity , 2001, Nature Immunology.

[14]  S. Amadori,et al.  Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. , 2001, Blood.

[15]  S. Rangarajan,et al.  Use of recombinant factor VIIa for post‐operative haemorrhage in a patient with Glanzmann's thrombasthenia and human leucocyte antigen antibodies , 2001, British journal of haematology.

[16]  A. Seltsam,et al.  Treatment of refractory autoimmune haemolytic anaemia with anti‐cd20 (rituximab) , 2001, British journal of haematology.

[17]  H. Lazarus,et al.  Chronic graft-versus-host disease: clinical manifestation and therapy , 2001, Bone Marrow Transplantation.

[18]  C. Anasetti,et al.  Advances in transplantation tolerance , 2001, The Lancet.

[19]  F. Locatelli,et al.  Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. , 2001, Blood.

[20]  Michael Loran Dustin,et al.  The immunological relay race: B cells take antigen by synapse , 2001, Nature Immunology.

[21]  M. Neuberger,et al.  B cells acquire antigen from target cells after synapse formation , 2001, Nature.

[22]  S. Davies,et al.  Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  M. Baccarani,et al.  Rituximab for myasthenia gravis developing after bone marrow transplant , 2000, Neurology.

[24]  H. Greinix,et al.  Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. , 2000, Blood.

[25]  K. Elkon,et al.  Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity. , 2000, The Journal of clinical investigation.

[26]  W. Murphy.  Revisiting graft-versus-host disease models of autoimmunity: new insights in immune regulatory processes. , 2000, The Journal of clinical investigation.

[27]  G. Yanik,et al.  Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host Disease , 2000, Annals of Internal Medicine.

[28]  P. Clements.  Systemic sclerosis (scleroderma) and related disorders: clinical aspects. , 2000, Bailliere's best practice & research. Clinical rheumatology.

[29]  A. Pestronk,et al.  IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab , 1999, Neurology.

[30]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  F. Locatelli,et al.  Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. , 1996, Bone marrow transplantation.

[32]  J. Niland,et al.  Thalidomide as salvage therapy for chronic graft-versus-host disease. , 1995, Blood.

[33]  D. Jabs,et al.  Thalidomide for the treatment of chronic graft-versus-host disease. , 1992, The New England journal of medicine.

[34]  H. Deeg,et al.  Thalidomide for treatment of patients with chronic graft-versus-host disease. , 2000, Blood.